about
Immunotherapy advances for glioblastomaImmunotherapy for primary brain tumors: no longer a matter of privilegeAre BiTEs the "missing link" in cancer therapy?Enzyme redesign guided by cancer-derived IDH1 mutationsMelanoma immunotherapy using mature DCs expressing the constitutive proteasome.Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.Clinical applications of a peptide-based vaccine for glioblastoma.A comprehensive outlook on intracerebral therapy of malignant gliomas.Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.Antibody-based immunotherapy for malignant glioma.Epidermal growth factor receptor and variant III targeted immunotherapy.Recurrent malignant gliomas.Immunotherapy for malignant gliomaTargeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.Poliovirus receptor CD155-targeted oncolysis of gliomaProteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.Regulatory T cells move in when gliomas say "I Do".Emerging immunotherapies for glioblastomaDifferential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomasDetection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery.A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.The role of tregs in glioma-mediated immunosuppression: potential target for intervention.The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patientsParaganglioma of the head and neck: long-term local control with radiotherapy.Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.Immunotherapy approaches for malignant glioma from 2007 to 2009.Clinical trial end points for high-grade glioma: the evolving landscape.Thickness of subcutaneous fat as a risk factor for infection in cervical spine fusion surgery.
P50
Q26866513-A560BCCB-AF74-45A2-81D0-D70DEC05DF79Q27002510-CB6B505F-47A5-4402-BE16-62D4CC757A6BQ28083907-5CCC1C4F-549F-4CF1-8728-F9FE2F196EE6Q28714280-728DDB0F-2712-46DA-8D15-75B11B45E786Q30541002-C3A58AF8-B1A2-4C6E-8E43-226016ED3C39Q30872793-5CCC0193-3985-4393-9998-5E511B0A8E78Q33665884-99F34EBB-59DA-4284-B7FB-072FE62144B3Q33668575-A3233F8D-EB1D-4A7F-8D60-D688CAC94A84Q33708333-C4B7D8BD-C7BA-4890-AD04-1388E6A96C76Q33761585-A6A45271-6E72-45E1-B9AE-DFF8C1C90BD7Q34120472-BBD80A4A-A8D6-4E9A-8003-229F3499BDA9Q34391942-7802D192-E76C-4D60-949C-948B696E7E29Q34438507-C2530B42-64E7-44A6-BF10-00C348BBFBCEQ35114086-83135A78-E623-4865-B4FC-FFCE9CA096ECQ35145392-ED581222-3EBC-4D45-95B6-93AAA285CC4BQ35162266-B6268CF3-8B77-432A-A145-F5AC19285F30Q35608531-987AE089-CABE-4622-8628-6A2F11E4016DQ35783111-C79728CC-BEA8-4C4E-88D1-B07BE89B8B29Q35800762-7D8D37E3-59A0-44B0-B99E-9AFEA850DAEFQ35887828-CBA50E45-7142-40E6-8DEB-785B1FEEA536Q36512160-54425A96-4CF4-4850-B449-335C27DD0816Q36558234-83AE4609-E823-4570-A678-32DDA3BB14B8Q36639475-A816DEC9-4484-44B6-9A04-200D2581FEE7Q36872066-A3C4C272-2423-4EC8-9950-4973C6210835Q37025105-3336B8BA-2DBC-445E-A08F-09ABB46B29C1Q37040617-E8BD333E-1472-42B3-B3C9-925E922E1407Q37102753-8EDA6AC9-C351-45F7-BCC4-091B2E0145DFQ37226704-50C954B8-FA08-4ABE-A090-6446D054D288Q37301009-65B6AB25-2968-4A5E-9782-81B43C40F3C1Q37362636-BA480635-E10C-4D4D-83BC-B2044E298101Q37402375-32B42770-C3FF-49FD-AD0D-8C3D69D3714DQ37452411-B462E327-1547-4BBD-9792-5AB0E8A630B4Q37475929-19052F78-F6AF-48FB-B573-CAC591A04143Q37477941-CEC586B8-A818-411E-A55A-5F70B80B4D4EQ37598166-60F6BD47-AA71-47BC-B990-1F00508D2B0CQ37616489-E1295A04-C50D-4E87-830F-46740822F183Q37618652-1F32E312-639D-413B-BD9D-9FDE4F4A46F2Q37738055-EACE7C36-1A7C-4A39-92BD-09FA5B10DA33Q37839482-1AF529D5-5833-41C1-AF83-7C2B6D23ADFAQ38083231-2EDFC4AD-D2A4-4D89-8A9C-6201B7A6B954
P50
description
researcher
@en
name
J H Sampson
@en
J H Sampson
@nl
type
label
J H Sampson
@en
J H Sampson
@nl
prefLabel
J H Sampson
@en
J H Sampson
@nl
P106
P31
P496
0000-0002-0104-7658